In the past several years, androgen deprivation therapy (ADT) and next-generation androgen receptor pathway inhibitors (ARPI) when combined with poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the way we treat metastatic prostate cancer (mPCa) (1, 2). The gene discussed is AR; the disease is metastatic prostate carcinoma.